SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-233526
Filing Date
2023-09-12
Accepted
2023-09-12 16:42:01
Documents
14
Period of Report
2023-09-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d485303d8k.htm   iXBRL 8-K 23862
2 EX-99.1 d485303dex991.htm EX-99.1 7998
6 GRAPHIC g485303g0913012207973.jpg GRAPHIC 8600
  Complete submission text file 0001193125-23-233526.txt   168527

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigr-20230912.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20230912_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20230912_pre.xml EX-101.PRE 11264
8 EXTRACTED XBRL INSTANCE DOCUMENT d485303d8k_htm.xml XML 3424
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 231250614
SIC: 2836 Biological Products, (No Diagnostic Substances)